INNOVIVA, INC. Payments to Noncontrolling Interests
INNOVIVA, INC. (INVA) reported Payments to Noncontrolling Interests of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaymentsToMinorityShareholders · last filed 2025-02-26
- INNOVIVA, INC. payments to noncontrolling interests for the quarter ending 2023-12-31 was $0.00.
- INNOVIVA, INC. payments to noncontrolling interests for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. payments to noncontrolling interests for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. payments to noncontrolling interests for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. payments to noncontrolling interests for fiscal 2024 was $0.00.
- INNOVIVA, INC. payments to noncontrolling interests for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- INNOVIVA, INC. payments to noncontrolling interests for fiscal 2022 was $69.81M, a 17.41% increase from fiscal 2021.
- INNOVIVA, INC. payments to noncontrolling interests for fiscal 2021 was $59.46M, a 95.11% increase from fiscal 2020.
| Period end | Payments to Noncontrolling Interests 3 month | Payments to Noncontrolling Interests 6 month | Payments to Noncontrolling Interests 9 month | Payments to Noncontrolling Interests 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-26 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $0.00 10-Q · filed 2023-11-01 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $53.76M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $53.76M derived: sum of 3 quarters · filed 2025-02-26 | $63.30M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $53.76M derived: sum of 2 quarters · filed 2025-02-26 | $63.30M derived: sum of 3 quarters · filed 2025-02-26 | $69.81M 10-K · filed 2025-02-26 |
| 2022-09-30 | $53.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $63.30M derived: sum of 2 quarters · filed 2023-11-01 | $69.81M 10-Q · filed 2023-11-01 | $82.91M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $9.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $16.05M 10-Q · filed 2023-08-02 | $29.15M derived: sum of 3 quarters · filed 2024-03-05 | $34.06M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $6.51M 10-Q · filed 2023-05-09 | $19.61M derived: sum of 2 quarters · filed 2024-03-05 | $24.52M derived: sum of 3 quarters · filed 2024-03-05 | $44.68M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $13.10M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $18.01M derived: sum of 2 quarters · filed 2024-03-05 | $38.17M derived: sum of 3 quarters · filed 2024-03-05 | $59.46M 10-K/A · filed 2024-03-05 |
| 2021-09-30 | $4.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $25.07M derived: sum of 2 quarters · filed 2022-11-09 | $46.36M 10-Q · filed 2022-11-09 | $48.87M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $20.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $41.45M 10-Q · filed 2022-07-27 | $43.96M derived: sum of 3 quarters · filed 2023-02-28 | $43.96M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $21.29M 10-Q · filed 2022-05-05 | $23.80M derived: sum of 2 quarters · filed 2023-02-28 | $23.80M derived: sum of 3 quarters · filed 2023-02-28 | $35.95M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.51M derived: sum of 2 quarters · filed 2023-02-28 | $14.66M derived: sum of 3 quarters · filed 2023-02-28 | $30.47M 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $12.15M derived: sum of 2 quarters · filed 2021-10-27 | $27.96M 10-Q · filed 2021-10-27 | $27.96M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $12.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $27.96M 10-Q · filed 2021-07-29 | $27.96M derived: sum of 3 quarters · filed 2022-03-17 | $38.52M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | $15.81M 10-Q · filed 2021-04-28 | $15.81M derived: sum of 2 quarters · filed 2022-03-17 | $26.36M derived: sum of 3 quarters · filed 2022-03-17 | $26.36M derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $10.55M derived: sum of 2 quarters · filed 2022-03-17 | $10.55M derived: sum of 3 quarters · filed 2022-03-17 | $10.55M 10-K/A · filed 2022-03-17 |
| 2019-09-30 | $10.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $10.55M derived: sum of 2 quarters · filed 2020-10-28 | $10.55M 10-Q · filed 2020-10-28 | $13.62M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $0.00 10-Q · filed 2020-07-29 | $3.07M derived: sum of 3 quarters · filed 2021-02-25 | $5.06M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $0.00 10-Q · filed 2020-04-29 | $3.07M derived: sum of 2 quarters · filed 2021-02-25 | $5.06M derived: sum of 3 quarters · filed 2021-02-25 | $5.87M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.06M derived: sum of 2 quarters · filed 2021-02-25 | $5.87M derived: sum of 3 quarters · filed 2021-02-25 | $5.96M 10-K · filed 2021-02-25 |
| 2018-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $2.80M derived: sum of 2 quarters · filed 2019-10-30 | $2.89M 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $809.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $899.00K 10-Q · filed 2019-07-24 | ||
| 2018-03-31 | $90.00K 10-Q · filed 2019-05-01 | |||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $0.00 derived: sum of 2 quarters · filed 2018-10-31 | $0.00 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $0.00 10-Q · filed 2018-07-26 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |